10-Q: Estrella Immunopharma Reports Q3 Losses Amid Clinical Trial Progress

Estrella Immunopharma, a clinical-stage biopharmaceutical company, reported increased net losses and expenses for Q3 2025, while advancing its STARLIGHT-1 clinical trial and addressing internal control weaknesses.

Summary

• Reported a net loss of $4.8 million for the three months ended September 30, 2025, compared to $3.4 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $12.5 million, up from $7.8 million in the prior year.
• Research and development expenses significantly increased to $10.2 million for the nine months ended September 30, 2025, from $6.4 million in 2024, driven by higher service fees and patient dosings in the STARLIGHT-1 clinical trial.
• General and administrative expenses rose to $2.2 million for the nine months ended September 30, 2025, from $1.4 million in 2024, primarily due to professional fees and stock-based compensation.
• Cash and cash equivalents stood at $1.6 million as of September 30, 2025, with an accumulated deficit of $36.4 million.
• The company's total stockholders' equity moved into a deficit of $9.8 million as of September 30, 2025, from a positive $143,731 at December 31, 2024.
• Nine patients have been dosed in the Phase I/II STARLIGHT-1 clinical trial as of September 30, 2025, with Phase I dosing completed in November 2025.
• A material weakness in internal control over financial reporting was identified due to a lack of qualified full-time personnel for complex U.S. GAAP accounting issues, despite ongoing remediation efforts.

Sentiment

Score: 3

Explanation: The company is making clinical progress with its STARLIGHT-1 trial, including completing Phase I dosing. However, this progress comes with significantly increased losses, a growing accumulated deficit, negative stockholders' equity, and a material weakness in internal controls. While some capital has been raised, the overall financial health is deteriorating, and future funding remains a critical dependency, making the outlook challenging despite clinical advancements.

Positives

• Completion of Phase I dosing for the STARLIGHT-1 clinical trial in November 2025, indicating progress in clinical development.
• Nine patients dosed in the STARLIGHT-1 clinical trial as of September 30, 2025, up from two patients in the prior year, demonstrating patient enrollment progress.
• Activation of a second clinical trial site for STARLIGHT-1, expanding trial capacity.
• Net cash used in operating activities decreased to $1.6 million for the nine months ended September 30, 2025, from $6.7 million in the prior year, indicating improved operational cash burn efficiency.
• Successfully raised approximately $2.4 million in gross proceeds from Securities Purchase Agreements between May and September 2025.
• Management believes it has sufficient funds on hand and ability to raise funds in the future through the issuance and sale of Equity Line Shares to White Lion in order to meet its working capital requirements and debt obligations, for at least the next 12 months from the filing date.

Negatives

• Increased net loss to $4.8 million for the three months ended September 30, 2025, from $3.4 million in the prior year.
• Accumulated deficit grew significantly to $36.4 million as of September 30, 2025, from $23.9 million at December 31, 2024.
• Total stockholders' equity turned into a deficit of $9.8 million as of September 30, 2025, from a positive $143,731 at December 31, 2024.
• Total liabilities increased substantially to $13.4 million as of September 30, 2025, from $3.0 million at December 31, 2024, primarily due to accrued related party liabilities and derivative liabilities.
• Working capital deficit of approximately $11.3 million as of September 30, 2025.
• Significant increase in research and development expenses to $10.2 million for the nine months ended September 30, 2025, from $6.4 million in 2024.
• General and administrative expenses also increased to $2.2 million for the nine months ended September 30, 2025, from $1.4 million in 2024.
• Identified a material weakness in internal control over financial reporting due to a lack of qualified personnel for complex U.S. GAAP accounting issues, and disclosure controls were not effective as of September 30, 2025.

Risks

• Ability to fund operations is highly dependent on raising additional debt or equity financing, with no assurance of availability on acceptable terms.
• Expectation of continued losses and negative cash flows from operations until product candidates receive regulatory approval and generate sufficient revenue.
• Future operations are highly dependent on the success of research and development programs, timely completion of additional financing, and regulatory approval.
• Reliance on Eureka Therapeutics, Inc. for technical assistance, manufacturing, and R&D activities; inability to replace these services could have a material adverse effect.
• The Equity Line Agreement with White Lion for up to $50 million is subject to limitations, including a 20% issuance cap without majority stockholder approval, which has not been obtained.
• Public warrants are unlikely to be exercised given the current stock price ($2.56 as of November 5, 2025) is significantly lower than the exercise price ($11.50), limiting this as a source of liquidity.
• Potential for third parties to assert infringement claims based on existing or future patents.
• Impact of inflation rates, the continuing military action in Ukraine, and Israel's war against Hamas could negatively affect financial position and results of operations.

Future Outlook

The company anticipates significant increases in expenses as it continues to advance preclinical and clinical development of product candidates, seek regulatory approval, scale clinical and regulatory capabilities, adapt to compliance requirements for marketed products, expand intellectual property, and build operational and management systems. It expects to incur additional legal, accounting, and public company operating expenses. The company does not expect to generate revenue for at least the next few years and its ability to do so is contingent on regulatory approval and successful commercialization.

Management Comments

• Management believes that the company has sufficient funds on hand and ability to raise funds in the future through the issuance and sale of Equity Line Shares to White Lion in order to meet its working capital requirements and debt obligations, for at least the next 12 months from the filing date.
• Management believes that the financial institution holding cash is of high credit quality and continually monitors their credit-worthiness.

Industry Context

Estrella Immunopharma operates in the highly competitive and capital-intensive clinical-stage biopharmaceutical industry, specifically focusing on T-cell therapies for blood cancers and solid tumors. The development of novel cell therapies like ARTEMIS technology for CD19 and CD22 targets represents a high-risk, high-reward area. Success is heavily dependent on clinical trial outcomes, regulatory approvals, and significant ongoing funding, which is typical for companies at this stage. The reliance on a related party (Eureka) for core R&D and manufacturing services is a notable aspect of its operational model, common in early-stage biotech where specialized expertise and infrastructure are shared or licensed.

Comparison to Industry Standards

• As a clinical-stage biopharmaceutical company with no revenue, direct comparison to revenue-generating industry benchmarks is not applicable.
• The company's significant R&D expenses and accumulated deficit are typical for biotech firms in the clinical development phase, where substantial investment is required before potential commercialization.
• The reliance on an equity line of credit and private placements for funding is a common strategy for early-stage biotech companies to manage liquidity and finance ongoing trials.
• The identification of a material weakness in internal controls, while a negative, is not uncommon for smaller, rapidly growing public companies transitioning from private operations, though remediation is critical for investor confidence.

Corporate Governance

Legal Proceedings

• The company is or may be party to certain legal proceedings and claims from time to time, but amounts accrued and reasonably possible losses are not deemed material to the financial statements.
• Third parties may assert infringement claims against the company, its licensors, or strategic collaborators.

Related Party Transactions

• Eureka Therapeutics, Inc. (Eureka) is a significant related party, holding 66.9% of the company on a fully diluted basis as of September 30, 2025.
• The company has an exclusive License Agreement with Eureka for T-cell therapies targeting CD19 and CD22, with Eureka responsible for manufacturing and supply.
• A Services Agreement with Eureka outlines Eureka's performance of R&D activities for Estrella.
• A Statement of Work (SOW) with Eureka details clinical trial services for STARLIGHT-1, with total fees of $33.0 million for all milestones. As of September 30, 2025, $3.5 million has been paid for achieved milestones, and $1.5 million deposited for patient treatment expenses. Accrued liabilities to Eureka for dosing milestones and second site activation totaled $12.9 million.
• The company subleases office space from Eureka for $2,000 per month.
• CoFame Investment Holding LLC, whose manager is a director of the company, provides advisory and consulting services in Asia. The company accrued $18,333 in unpaid consulting fees to CoFame as of September 30, 2025.

Stakeholder Impact

• **Shareholders**: Face increased financial risk due to growing losses, negative equity, and reliance on future capital raises. Clinical progress offers potential long-term value but is offset by short-term financial deterioration and internal control issues. The potential for 'True-Up Shares' could dilute existing shareholders if the stock price falls below $1.50.
• **Employees**: Continued R&D activities and clinical trial progress suggest ongoing employment stability in core development areas, but the company's financial health could impact future growth opportunities or compensation structures.
• **Customers (future)**: The advancement of clinical trials for EB103 and EB104 brings the company closer to potentially offering new T-cell therapies for blood cancers and solid tumors, which could benefit patients in the future.
• **Creditors/Suppliers**: Increased liabilities and negative equity may raise concerns for creditors, although management believes it has sufficient funds for the next 12 months. Eureka, as a major related party and service provider, is a significant creditor.
• **Regulatory Authorities**: The identified material weakness in internal controls highlights a need for improved financial reporting processes, which regulatory bodies like the SEC monitor closely.

Next Steps

• Continue to advance preclinical and clinical development of product candidates and preclinical programs.
• Seek regulatory approval for any product candidates that successfully complete clinical trials.
• Scale up clinical and regulatory capabilities.
• Adapt regulatory compliance efforts for marketed products.
• Maintain, expand, and protect the intellectual property portfolio.
• Add operational, financial, and management information systems and personnel to support product development and future commercialization.
• Address the identified material weakness in internal control over financial reporting by adding qualified personnel and implementing robust processes.
• Potentially seek stockholder approval for issuing Equity Line Shares exceeding 20% of outstanding common stock.

Key Dates

Recommendation

Estrella Immunopharma presents a high-risk investment profile. While clinical progress with the STARLIGHT-1 trial is a positive, the company's financial position has significantly deteriorated, marked by substantially increased net losses, a growing accumulated deficit, and negative stockholders' equity. The material weakness in internal controls raises concerns about financial reporting reliability. The company is heavily reliant on future capital raises, which are uncertain and potentially dilutive, especially given the current stock price is well below warrant exercise prices and the 'True-Up Shares' feature. The significant increase in liabilities, particularly to a related party, further complicates the financial outlook. Given these substantial financial and operational challenges, a seasoned investor would likely recommend selling or avoiding the stock until there is clear evidence of financial stabilization, successful clinical outcomes, and robust internal controls.

Keywords

T-cell therapy, biopharmaceutical, clinical-stage, CD19, CD22, ARTEMIS platform, STARLIGHT-1, EB103, EB104, oncology, blood cancers, solid tumors, non-Hodgkin lymphoma, SEC filing, 10-Q, financial results, research and development, liquidity, capital raise, internal controls